Ardsley Advisory Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ardsley Advisory Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-50,000	Closed	-$6.64M	–	169
2015 Q3	$6.64M	Buy	+50,000	New	+$8.61M	1.61%	19

Other funds holding JAZZ

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

ACM

Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BCM

BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Ardsley Advisory Partners's JAZZ Position: Q2 2026 in Review

Ardsley Advisory Partners opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 30,000 shares worth $7.23M. The stake represents 0.75% of the portfolio and ranks #46 among its holdings. This is a return to the name: Ardsley Advisory Partners previously reported a position in JAZZ as recently as Q4 2025.

Ardsley Advisory Partners first reported a position in JAZZ in Q2 2013 and has held it in 26 quarters since. The position peaked at $44.8M in Q2 2014. 130 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Ardsley Advisory Partners held 30,000 shares of Jazz Pharmaceuticals worth $7.23M as of Q2 2026.
Jazz Pharmaceuticals was a new Ardsley Advisory Partners position in Q2 2026.
Jazz Pharmaceuticals made up 0.75% of Ardsley Advisory Partners's portfolio in Q2 2026, its #46 holding.
Ardsley Advisory Partners first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
Ardsley Advisory Partners's Jazz Pharmaceuticals position peaked at $44.8M in Q2 2014.
130 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Ardsley Advisory Partners's 13F filing for Q2 2026, filed 13 Jul 2026.